The article delves into the triple-action weight-loss injection known as retatrutide manufactured by Eli Lilly. This injection, currently in later-stage human clinical trials, mimics three hormones in the body that affect hunger and blood sugar levels.
Expected to be approved for individuals with obesity and type 2 diabetes, retatrutide has shown significant weight loss results in trials. A recent study found that participants lost an average of 24% of their weight after 48 weeks on the drug, with some participants losing over 30%. The medication is expected to be more effective than other weight-loss treatments like semaglutide and tirzepatide.
While retatrutide is not yet available in the UK or U.S., it is undergoing further trials for broader populations. The drug is a potential game-changer in weight loss medication, with promising results in terms of both weight loss and health improvement.
The three hormones that retatrutide mimics are:
- GLP-1: Lowers appetite and blood sugar levels
- GIP: Lowers appetite and blood sugar levels
- Glucagon: Promotes fat breakdown for energy use and prevents low blood sugar levels
The triple action of retatrutide means it has a profound effect on appetite and the management of blood sugar levels and is expected to be more effective than semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) for weight loss
